Clinical trials · Baltimore, MD
Diffuse Midline Glioma, H3 K27M-Mutant clinical trials in Baltimore
We’re tracking 6 recruiting diffuse midline glioma, h3 k27m-mutant studies with a site in or near Baltimore — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies near Baltimore
- NCT05099003RecruitingPhase 1/Phase 2
Selinexor plus radiation for newly diagnosed brain tumors
This trial studies whether adding selinexor to standard radiation can improve outcomes for children and young teens with certain newly diagnosed high-grade brain tumors (including DIPG). It’s designed for specific tumor types and genetic markers, and people must be able to start treatment soon after diagnosis.
Baltimore, MarylandAges 1–21 - NCT05009992RecruitingPhase 2
Drug combination for diffuse midline gliomas in children and young adults
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
Baltimore, MarylandAges 2–39 - NCT04541082RecruitingPhase 1
Oral ONC206 for recurrent brain and spinal tumors
This early-phase study tests an oral medicine called ONC206 in adults with recurrent, rare brain or spinal cord tumors. The goal is to find a safe dose and look for signs the treatment can shrink or control the cancer.
Bethesda, MarylandAges 18 years+ - NCT06161974RecruitingPhase 2
Olutasidenib and temozolomide for IDH1-mutant high-grade glioma
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
Washington D.C., District of ColumbiaAges 12–39 - NCT05839379Recruiting
Targeted therapy study for children and young adults with brain tumors
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
Washington D.C., District of ColumbiaAges 1–39 - NCT05843253RecruitingPhase 2
Ribociclib plus everolimus or temozolomide for certain brain tumors
This Phase 2 study tests ribociclib with either everolimus or temozolomide, depending on the specific brain tumor type. It may help slow tumor growth in children and young adults whose tumor has specific genetic changes and who have had recent standard radiation therapy.
Washington D.C., District of ColumbiaAges 1–39
Hear when a new Diffuse Midline Glioma, H3 K27M-Mutant trial opens near Baltimore, MD
We’ll email you when one opens near Baltimore, MD — at most once a week, no account needed, unsubscribe anytime.
Diffuse Midline Glioma, H3 K27M-Mutant trials in other cities
Where these studies are running near Baltimore
Institutions with a site for the recruiting diffuse midline glioma, h3 k27m-mutant studies listed above.
- Children's National Medical Center · 5 studies
- Johns Hopkins University
- National Institutes of Health Clinical Center
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
What taking part in a diffuse midline glioma, h3 k27m-mutant study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there diffuse midline glioma, h3 k27m-mutant clinical trials near Baltimore?
- Yes. We're currently tracking 6 recruiting diffuse midline glioma, h3 k27m-mutant studies with a site near Baltimore, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a diffuse midline glioma, h3 k27m-mutant study near Baltimore?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Baltimore to take part?
- Not necessarily. These studies have a site near Baltimore, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a diffuse midline glioma, h3 k27m-mutant trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New diffuse midline glioma, h3 k27m-mutant studies open near Baltimore regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.